The campaign theme this year is the Value of Biosimilar medicines. Each day of the week we encourage supporters to share different aspects of biosimilar’s value in social media. Click the arrows below for more details and see sample messages in the social toolkit.
Biosimilars: Value for patients
Biosimilars: Value for healthcare professionals, providers and clinical practice
Biosimilars: Value for governments and healthcare systems
Biosimilars: Value for regulators
Join the Biosimilars Movement!
When competition kicks in, we need policies in place supporting the reinvestment of the savings in more patients having access.
Suzette Kox, IGBA Secretary General
With 15 years of positive biosimilar medicines contribution to patient health and healthcare system sustainability, the challenges and remedies to efficient use of biosimilar medicines are well known.
Julie Maréchal-Jamil, Co-Chair, IGBA Biosimilars Committee
The COVID-19 global health crisis has led governments and the entire healthcare community to rethink and rebuild healthcare systems; this includes focusing on their ability to efficiently deliver access to biologic therapies and to effectively address non-communicable diseases.
Sudarshan Jain, IGBA Past Chair
Our last interview during our third Global Biosimilars Week features Dr Cary Adams, CEO of the Union for International Cancer Control (UICC) and Suzette Kox, IGBA Secretary General. It covers the relatively new UICC initiative, namely a different approach to access by the Access to Oncology Medicines (ATOM) Coalition and how biosimilar medicines companies can play a role in the Coalition’s ambition of improving access to essential cancer medicines.
Biosimilar medicines hold the potential to enable equitable access to biologic therapies for patients around the world. The IGBA’s 2021 Biosimilar medicines Access Policy Blueprint identified four key areas where global collaborative action can help achieve the potential for biosimilar medicines.
This paper further elaborates on one of the key areas: Enhancing Regulatory Efficiency for Greater Access.
It discusses how the revised 2022 WHO Biosimilars Guideline (the Guideline) provides a timely opportunity to collectively re-evaluate the way in which regulatory requirements can better advance biosimilar access. The Guideline defines globally acceptable principles for licensing biological products that can be used to harmonize biosimilar medicines regulations around the world. If cohesively adopted by national regulatory authorities, the Guideline can promote more efficient regulatory systems to provide patients with earlier access to safe, effective, high-quality, and lowercost biosimilar medicines.
View these educational modules to learn how the biosimilar landscape began and how patients and health care systems benefit from biosimilar medicines around the globe.
Since 1980, biological medicines, which are highly complex treatments made by or derived from a biological source, have grown to become an indispensable tool in modern medicine. These safe and effective medicines are targeted to treat many rare and serious diseases and millions of patients have already benefited from these treatments.
Health care systems around the globe are under financial stress due to the pandemic, an aging population and rising prevalence of chronic conditions, with pharmaceutical spending expected to reach $1.6 trillion USD globally in the coming years. Biological medicines, while an important tool in treating certain conditions, come at a very high cost and hence are inaccessible for many patients.
Biosimilar medicines are biological medicines that are developed to be highly similar to an existing biological medicine, but are more cost-effective. Today, hundreds of biosimilar medicines have been approved around the globe, which brought competition to the marketplace after patent expiry of the original biological. This has produced huge savings and eased financial stress on health care systems and substantially increased patients access to biological treatments.
With biosimilar medicines, patients and healthcare providers benefit from quality-assured and efficacious therapeutic alternatives. Biosimilar medicine development is target-oriented and comparative, requiring significant investment and state-of-the-art technologies. Extensive evidence is required to demonstrate that a biosimilar medicine is as safe and effective as its reference biologic. Additionally, the same high regulatory standards apply as for any other medicine.
Greater competition introduced by biosimilar medicines has many benefits for patients, providers, and health care systems around the world. Biosimilar medicines give providers a broader range of treatment options for their patients and give more patients access to biological treatments. Additionally, by representing cost-effective alternatives to reference biologicals, biosimilar medicines offer health care systems huge savings for the same clinical outcome.
Biosimilar medicines have become an integral part of our health care systems. Today, they are internationally recognized for expanding access to life-saving treatments. Building on the experience and the success of biosimilar medicines supports their increased uptake and safeguards the medical supply chain.
View organizations or activities helping to build a better future with biosimilar medicines.
PARTICIPATING IN GBW IGBA MEMBER GBW MEDIA PARTNER
To add a biosimilars related event or link on the global map, submit the form below.